Personalized Cancer Vaccines Face Manufacturing Hurdles

The recent phase 3 clinical trial success of Merck and Moderna's personalized melanoma vaccine has brought attention to the manufacturing challenges facing the development of such treatments.

The personalized cancer vaccine field requires pharma manufacturing to adapt, as each treatment is tailored to an individual patient's specific mutations.

Amy Walker, CEO of 4basebio and co-chair of the Alliance for mRNA Medicines' European Committee, noted that scaling up production to meet demand will be a significant challenge.

The process involves biopsying tumors, genetically sequencing both tumor and healthy blood cells, identifying mutations, and creating synthetic mRNA encoding neoantigens. This requires high-tech computational tools and an enormous 'scale-out' architecture to produce tens of thousands of individual batches.